U.S. MARKETS FOR PHARMACOLOGIC AND DEVICE-BASED APPROACHES TO PAIN MANAGEMENT

192 Pages | 43 Exhibits | 2014 Analysis | Forecasts Through 2018

OVERVIEW:
Pain is the single most common reason patients seek medical care, accounting for approximately half of all physician office visits in the United States (U.S.); some studies suggest that more than one-third of people in the U.S. suffer from a chronic pain condition at some point in their lives.

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).

During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Pain Management Pharmaceuticals
	a. Nonprescription Analgesics and Anesthetics
		i. Nonprescription Systemic Analgesics
		ii. Nonprescription Topical Analgesics
		iii. Market Forecast
	b. Prescription Analgesics and Anesthetics
		i. Prescription Non-Steroidal Anti-Inflammatory Drugs
		ii. Opioid Analgesics
		iii. Opioid/Nonopioid Combination Analgesics
		iv. Antimigraine Analgesics
		v. Adjuvant Analgesics
		vi. General, Regional, and Local Anesthetics
		vii. Market Forecast
	c. Combined Market Forecast
ii. Pain Management Devices
	a. Electrical Stimulators
		i. Transcutaneous Electrical Nerve Stimulators
		ii. Neurostimulators
		iii. Market Forecast
	b. Analgesia Infusion Pumps
		i. Implantable Analgesia Infusion Pumps
		ii. External Analgesia Infusion Pumps
		iii. Market Forecast
	c. Combined Market Forecast
iii. Combined Market Forecast
 
Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018
Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018
Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018
Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018
Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018
 
1. PAIN MANAGEMENT OVERVIEW

1.1 Pain Physiology
	1.1.1 The Nervous System
	1.1.2 Pain Perception
	1.1.3 Pain Classification
		1.1.3.1 Nociceptive Pain
		1.1.3.2 Non-Nociceptive Pain
		1.1.3.3 Acute Pain
		1.1.3.4 Chronic Pain
1.2 Pain Assessment Techniques
1.3 Pain Prevalence
1.4 Common Pain Syndromes
	1.4.1 Arthritis Pain
	1.4.2 Back Pain
	1.4.3 Burn Pain
	1.4.4 Cancer Pain
	1.4.5 Headache Pain
	1.4.6 Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain
	1.4.7 Obstetric Pain
	1.4.8 Podiatric Pain
	1.4.9 Sciatic Pain
	1.4.10 Temporomandibular Pain
	1.4.11 Trauma Pain
1.5 Clinical Approaches to Pain Management
	1.5.1 Pain Management Guidelines
	1.5.2 Pain Management Guidelines for Older Adults
	1.5.3 Interventional Pain Management Guidelines
	1.5.4 Pain Management Options
		1.5.4.1 Pharmaceutical Options
		1.5.4.2 Device-Based Options
		1.5.4.3 Alternative Therapy Options
 
Exhibit 1-1: Common Causes of Neuropathic Pain
Exhibit 1-2: United States Population, by Selected Ages, 1990-2050
Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management
 
2. PAIN MANAGEMENT PHARMACEUTICALS

2.1 Pharmaceutical Formulations and Drug Delivery
	2.1.1 Oral Drug Delivery
	2.1.2 Injection/Infusion Drug Delivery
		2.1.2.1 Injection
			2.1.2.1.1 Intramuscular Injection
			2.1.2.1.2 Subcutaneous Injection
		2.1.2.2 Infusion
			2.1.2.2.1 Intravenous Infusion
			2.1.2.2.2 Intraspinal Infusion
			2.1.2.2.3 Intraoperative Site Infusion
	2.1.3 Inhalation Drug Delivery
	2.1.4 Transdermal Drug Delivery
	2.1.5  Transmucosal Drug Delivery
	2.1.6 Nonsteroidal Anti-Inflammatory Drugs
		2.1.6.1 Heart Attack and Hypertension Risks
		2.1.6.2 The Food and Drug Administration and Labeling
		2.1.6.3 Naproxen Risks
2.2 The Benefits of Aspirin
	2.2.1 Aspirin and Heart Attack/Stroke Prevention
	2.2.2 Aspirin and Heart Failure
	2.2.3 Aspirin and Cancer Prevention
2.3 Market Analysis
	2.3.1 Nonprescription Analgesics and Anesthetics
		2.3.1.1 Market Forecast
		2.3.1.2 Nonprescription Systemic Analgesics
			2.3.1.2.1 Acetaminophen
			2.3.1.2.2 Nonprescription Nonsteroidal Anti-Inflammatory Drugs
			2.3.1.2.3 Market Forecast
			2.3.1.2.4 Competitive Analysis
		2.3.1.3 Nonprescription Topical Analgesics and Anesthetics
			2.3.1.3.1 Amino Amides and Esters
			2.3.1.3.2 Capsaicin
			2.3.1.3.3 Methyl and Trolamine Salicylates
			2.3.1.3.4 Topical Patches
			2.3.1.3.5 Market Forecast
			2.3.1.3.6 Competitive Analysis
	2.3.2 Prescription Analgesics and Anesthetics
		2.3.2.1 Market Forecast
		2.3.2.2 Prescription Nonsteroidal Anti-Inflammatory Drugs
			2.3.2.2.1 Acetic Acid Derivatives
			2.3.2.2.2 Anthranilic Acid Derivatives
			2.3.2.2.3 Cyclooxygenase-2 Selective Inhibitors
			2.3.2.2.4 Enolic Acid Derivatives
			2.3.2.2.5 Propionic Acid Derivatives
			2.3.2.2.6 Salicylic Acid Derivatives
			2.3.2.2.7 Market Forecast
			2.3.2.2.8 Competitive Analysis
		2.3.2.3 Opioid Analgesics
			2.3.2.3.1 Buprenorphine
			2.3.2.3.2 Butorphanol
			2.3.2.3.3 Codeine
			2.3.2.3.4 Fentanyl
			2.3.2.3.5 Hydromorphone
			2.3.2.3.6 Levorphanol
			2.3.2.3.7 Meperidine
			2.3.2.3.8 Morphine
			2.3.2.3.9 Nalbuphine
			2.3.2.3.10 Oxycodone
			2.3.2.3.11 Oxymorphone
			2.3.2.3.12 Pentazocine
			2.3.2.3.13 Propoxyphene
			2.3.2.3.14 Remifentanil
			2.3.2.3.15 Tramadol
			2.3.2.3.16 Tapentadol
			2.3.2.3.17 Hydrocodone
			2.3.2.3.18 Market Forecast
			2.3.2.3.19 Competitive Analysis
		2.3.2.4 Opioid/Nonopioid Combination Analgesics
			2.3.2.4.1 Market Forecast
			2.3.2.4.2 Competitive Analysis
		2.3.2.5 Antimigraine Analgesics
			2.3.2.5.1 Diclofenac
			2.3.2.5.2 Dihydroergotamine
			2.3.2.5.3 Divalproex Sodium
			2.3.2.5.4 Triptans
			2.3.2.5.5 Market Forecast
			2.3.2.5.6 Competitive Analysis
		2.3.2.6 Adjuvant Analgesics
			2.3.2.6.1 Anticonvulsants
			2.3.2.6.2 Antidepressants
			2.3.2.6.3 Corticosteriods
			2.3.2.6.4 Market Forecast
			2.3.2.6.5 Competitive Analysis
		2.3.2.7 General, Regional, and Local Anesthetics
			2.3.2.7.1 Inhalation General Anesthetics
			2.3.2.7.2 Intravenous General Anesthetics
			2.3.2.7.3 Anesthetics Used in Balanced Anesthesia
			2.3.2.7.4 Regional/Local Anesthetics
			2.3.2.7.5 Market Forecast
			2.3.2.7.6 Competitive Analysis
	2.3.3 Combined Market Forecast
 
Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods
Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics
Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics
Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018
Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018
Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier
Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018
Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier
Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018
Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018
Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier
Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018
Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier
Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018
Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018
Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier
Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018
Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier
Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018
Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier
Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018
 
3. PAIN MANAGEMENT DEVICES

3.1 Electrical Stimulators
	3.1.1 Transcutaneous Electrical Nerve Stimulators
		3.1.1.1 Market Forecast
		3.1.1.2 Competitive Analysis
	3.1.2 Neurostimulators
		3.1.2.1 Occipital Nerve Stimulation
		3.1.2.2 Neuromuscular Stimulators
		3.1.2.3 Spinal Cord and Peripheral Nerve Stimulators
		3.1.2.4 Market Forecast
		3.1.2.5 Competitive Analysis
3.2 Analgesia Infusion Pumps
	3.2.1 Implantable Analgesia Infusion Pumps
		3.2.1.1 Market Forecast
		3.2.1.2 Competitive Analysis
	3.2.2 External Analgesia Infusion Pumps
		3.2.2.1 Nerve Block
		3.2.2.2 Patient-Controlled Analgesia Infusion Pumps
		3.2.2.3 Products
		3.2.2.4 Market Forecast
		3.2.2.5 Competitive Analysis
3.3 Combined Market Forecast
 
Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder
Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy
Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018
Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018
Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier
Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier
Exhibit 3-8: Implantable Analgesia Infusion Pumps,  Market Forecast, 2013-2018
Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier
Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018
Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier
Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018
 
4. COMPANY PROFILES

4.1 AstraZeneca PLC
4.2 Baxter Healthcare, Inc./Baxter International, Inc.
4.3 Bayer HealthCare AG/Bayer AG
4.4 Boston Scientific Corporation
4.5 CareFusion Corporation
4.6 Chattem, Inc./sanofi-aventis LLC
4.7 DJO Global, Inc.
4.8 Eli Lilly and Company
4.9 Endo Pharmaceutical Holdings, Inc./Endo International PLC
4.10 GlaxoSmithKline PLC
4.11 Hospira, Inc.
4.12 International Rehabilitative Sciences, Inc., d/b/a RS Medical
4.13 Johnson & Johnson
4.14 Medtronic, Inc.
4.15 Pfizer, Inc.
4.16 Purdue Pharma LP
4.17 Teva Pharmaceutical Industries LTD
 
APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Abbott Laboratories
  2. Actavis Pharmaceuticals PLC
  3. ALCiS Health, Inc.
  4. Allergan, Inc.
  5. American Imex, Inc.
  6. AstraZeneca PLC
  7. Baxter Healthcare, Inc./ Baxter International, Inc.
  8. Bayer AG
  9. Bayer HealthCare AG/Bayer AG
  10. B. Braun Medical, Inc./ B. Braun Melsungen AG
  11. Bedford Laboratories, Inc./ Hikma Pharmaceuticals PLC
  12. Beutlich Pharmaceuticals LLC
  13. B.F. Ascher & Company, Inc.
  14. BioMedical Life Systems, Inc.
  15. Blue Spring International LLC
  16. Boston Scientific Corporation
  17. CareFusion Corporation
  18. Chattem, Inc./sanofi-aventis LLC
  19. Depomed, Inc.
  20. DePuy, Inc./Johnson & Johnson
  21. DJO Global, Inc.
  22. Dynatronics Corporation
  23. Eli Lilly and Company
  24. Endo Pharmaceutical Holdings, Inc./Endo International PLC
  25. GlaxoSmithKline PLC
  26. Haw Par Corporation
  27. Hikma Pharmaceuticals PLC
  28. Hisamitsu America, Inc./ Hisamitsu Pharmaceutical Company, Inc.
  29. Horizon Pharma, Inc.
  30. Hospira, Inc.
  31. I-Flow LLC
  32. Insight Pharmaceuticals LLC
  33. International Rehabilitative Sciences, Inc., d/b/a RS Medical
  34. Iroko Pharmaceuticals, Inc.
  35. Janssen Pharmaceuticals, Inc./ Johnson & Johnson
  36. JHP Pharmaceuticals/ Par Pharmaceutical, Inc.
  37. Johnson & Johnson
  38. Kramer Laboratories, Inc.
  39. Mallinckrodt PLC
  40. McNeil Consumer Healthcare/ Johnson & Johnson
  41. Meda Pharmaceuticals, Inc./ Meda AB
  42. Medtronic, Inc.
  43. The Mentholatum Company, Inc.
  44. Merck & Company, Inc.
  45. Mettler Electronics Corporation
  46. Mission Pharmacal Company
  47. Moog, Inc.
  48. Nnodum Pharmaceuticals Corporation
  49. Novartis AG
  50. Otis Clapp & Buffington Pharmaceuticals, Inc.
  51. Par Pharmaceutical, Inc.
  52. Pfizer, Inc.
  53. Prestige Brands, Inc.
  54. Prizm Medical, Inc.
  55. Procter & Gamble Company
  56. Purdue Pharma LP
  57. Reckitt Benckiser Group PLC
  58. Rich-Mar Corporation
  59. Roche Pharmaceuticals/ F. Hoffman-La Roche AG
  60. sanofi-aventis LLC
  61. Shionogi & Company LTD
  62. Smiths Medical/Smiths Group PLC
  63. Stellar Health Products, Inc.
  64. St. Jude Medical, Inc.
  65. Stryker Corporation
  66. Teva Pharmaceutical Industries LTD
  67. Valeant Pharmaceuticals International, Inc.
  68. Walkmed Infusion LLC
  69. Zogenix, Inc.
Contact Us

Need help finding medtech research? Let us help you!